Cited by 285Myeloproliferative Neoplasms: Diagnosis and TreatmentCancer Genomics and DiagnosticsAcute Myeloid Leukemia Research

Life histories of myeloproliferative neoplasms inferred from phylogenies

Open access
Williams, Nicholas, Lee, Joe, Mitchell, Emily, Moore, Luiza, Baxter, E. Joanna, Hewinson, James, Dawson, Kevin J., Menzies, Andrew +4 more·2022·Nature

Published version of a preprint

Abstract

Mutations in cancer-associated genes drive tumour outgrowth, but our knowledge of the timing of driver mutations and subsequent clonal dynamics is limited 1-3. Here, using whole-genome sequencing of 1,013 clonal haematopoietic colonies from 12 patients with myeloproliferative neoplasms, we identified 580,133 somatic mutations to reconstruct haematopoietic phylogenies and determine clonal histories. Driver mutations were estimated to occur early in life, including the in utero period. JAK2 V617F was estimated to have been acquired by 33 weeks of gestation to 10.8 years of age in 5 patients in whom JAK2 V617F was the first event. DNMT3A mutations were acquired by 8 weeks of gestation to 7.6 years of age in 4 patients, and a PPM1D mutation was acquired by 5.8 years of age. Additional genomic events occurred before or following JAK2 V617F acquisition and as independent clonal expansions. Sequential driver mutation acquisition was separated by decades across life, often outcompeting ancestral clones. The mean latency between JAK2 V617F acquisition and diagnosis was 30 years (range 11-54 years). Estimated historical rates of clonal expansion varied substantially (3% to 190% per year), increased with additional driver mutations, and predicted latency to diagnosis. Our study suggests that early driver mutation acquisition and life-long growth and evolution underlie adult myeloproliferative neoplasms, raising opportunities for earlier intervention and a new model for cancer development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-021-04312-6

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 64 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Jolly, C. & Van Loo, P. Timing somatic events in the evolution of cancer. Genome Biol. 19, 95 (2018).

Cited by

Sorted by citations

Authors
Williams, N., Lee, J., Mitchell, E., Moore, L., Baxter, E. J., Hewinson, J., Dawson, K. J., Menzies, A., Godfrey, A. L., Green, A. R., Campbell, P. J., & Nangalia, J.
Affiliations
  • Wellcome Sanger Institute (GB)
  • Wellcome/MRC Cambridge Stem Cell Institute (GB)
  • University of Cambridge (GB)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
Corresponding author
Nangalia, Jyoti
Venue
Nature
Published
2022-01-20
Volume
602
Issue
7895
Pages
162-168
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4205211254
Cited by
285
References
64
Citations by year
2026: 40 · 2025: 52 · 2024: 74 · 2023: 65 · 2022: 52 · 2021: 1 · 2020: 1
FWCI
37.71
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • Research Square (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • MPN Research Foundation
  • Wellcome Trust (104710/Z/14/Z)
  • Cancer Research UK (23917)
  • Kay Kendall Leukaemia Fund
  • Blood Cancer UK
  • Medical Research Council (MC_PC_17230)
Topics
  • Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
myeloproliferative neoplasms, driver mutations, clonal evolution, JAK2 V617F mutation, DNMT3A, PPM1D, clonal expansion, mutation timing, carcinogenesis
MeSH terms
Protein Phosphatase 2C, Whole Genome Sequencing, Adult, Child, Preschool, Clone Cells, Humans, Mutation, Myeloproliferative Disorders, Neoplasms, Phylogeny, Janus Kinase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review